Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Neogen (NEOG) reported Q4 2025 revenue of $225.46 million, a 4.8% year-over-year decline, which slightly surpassed analyst estimates, but its EPS of $0.05 marked a significant 37.5% miss against consensus and a 50% drop from the prior year. Both Food Safety and Animal Safety segments saw revenue contractions, with Animal Safety declining 9% year-over-year. This mixed performance has led to Neogen's stock underperforming the broader market and receiving a Zacks Rank #4 (Sell), indicating potential near-term weakness.

Analysis

Neogen's fourth-quarter results reveal significant fundamental weakness despite a minor top-line beat. The company reported revenue of $225.46 million, a 1.9% surprise over consensus but a material 4.8% decline year-over-year, indicating contracting demand. The primary concern is the substantial deterioration in profitability, with earnings per share of $0.05 falling 50% from the prior year and missing the consensus estimate of $0.08 by a notable 37.5%. This earnings miss suggests severe margin pressure or operational inefficiencies. The revenue decline was broad-based, with the Food Safety segment down 3% YoY and the larger Animal Safety segment contracting by a more severe 9% YoY, also missing its specific revenue estimate. Within these segments, nearly every sub-division reported YoY declines, with Animal Care & Other dropping a steep 21%. The only exception was a minor 4.4% YoY growth in the Food Safety's Rodent Control sub-segment, which is insufficient to offset the widespread weakness. This poor operational performance is reflected in the stock's -4.9% return over the past month, starkly underperforming the S&P 500 composite's +3.4% gain, and is further underscored by its Zacks Rank #4 (Sell) designation, signaling expectations of continued near-term underperformance.

Key Decisions for Investors

• The significant EPS miss and broad-based year-over-year revenue declines, particularly the 9% drop in the Animal Safety segment, warrant a cautious to bearish stance on Neogen in the near term.
• Investors should scrutinize management's forward guidance for any concrete strategy to address margin compression and reverse the negative growth trends before considering a long position.
• Given the stock's recent market underperformance and the formal Zacks #4 (Sell) rating, current holders may consider reducing exposure, as the report signals fundamental challenges that could persist.